In re Seroquel Products Liability Litigation

244 F.R.D. 650, 2007 U.S. Dist. LEXIS 61287, 2007 WL 2412946
CourtDistrict Court, M.D. Florida
DecidedAugust 21, 2007
DocketNo. 6:06-md-1769-Orl-22DAB
StatusPublished
Cited by12 cases

This text of 244 F.R.D. 650 (In re Seroquel Products Liability Litigation) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Seroquel Products Liability Litigation, 244 F.R.D. 650, 2007 U.S. Dist. LEXIS 61287, 2007 WL 2412946 (M.D. Fla. 2007).

Opinion

[651]*651Order

BAKER, United States Magistrate Judge.

TO THE UNITED STATES DISTRICT COURT

This cause came on for consideration after hearing on the following motion filed herein:

MOTION: PLAINTIFFS’ MOTION FOR DISCOVERY SANCTIONS (Doc. No. 256)

FILED: July 3, 2007

THEREON it is ORDERED that the motion is GRANTED in part.

In this multidistrict litigation, Plaintiffs have sued Defendants for claims arising for alleged injuries from ingesting AstraZeneca’s Seroquel, an atypical anti-psychotic medication that allegedly can cause diabetes and related disorders. Doc. No. 1.

Plaintiffs have moved for sanctions based on AstraZeneca’s “failure to timely comply with numerous discovery obligations since the inception of this litigation” based on four categories of conduct. Doc. No. 256 at 1. Plaintiffs base their Motion for Sanctions, first, on AZ’s failure to produce, in a readable format, key elements of the IND/NDA in November 2006 as ordered, not producing a key element until June 2007. Second, Plaintiffs contend that AZ failed to produce organizational charts by January 2006 as ordered and withheld the vast majority of them until May 14, 2007. Third, Plaintiffs argue AZ failed to identify all relevant databases which it was obligated to identify in January 2007, instead identifying only a fraction; to date, Plaintiffs have now identified fifty-nine relevant databases. Fourth, Plaintiffs’ strongest contention is that, although AZ was to produce electronic discovery from its self-chosen “custodians” — -those employees most knowledgeable about Seroquel and its development — AZ waited until mid-May to begin production of the overwhelming majority of the documents and the documents actually produced have significant errors of omission and were not readable or searchable.

AZ contends that the Motion for Sanctions should be denied on procedural grounds because Plaintiffs have not successfully moved to compel and no sanctions are warranted because AZ has complied with the Court’s discovery orders. AZ argues that it has produced the entire IND/NDA to Plaintiffs; has produced organizational charts “early, [652]*652often, and abundantly”; its custodial production was timely and appropriate; and it has not violated any orders to produce databases.

The Court finds that some of the conduct Plaintiffs have complained of is not sanction-able, however, AZ’s custodial production issues, and its uncooperative efforts to resolve technical issues, are a violation of e-discovery rules and principles. AZ’s failure to produce Item 12 of the CANDA in the IND/NDA was oversight or excusable neglect. AZ’s failure to produce organizational charts per CMO 2 in a timely fashion was also the result of excusable neglect. However, AZ’s failure to cooperate in the production of the databases and its failure to timely and systematically produce electronic discovery associated with eighty AZ “custodians” in any manageable, searchable form are sanctionable conduct. The Court will reserve ruling on the appropriate sanctions pending further discovery and after Plaintiffs have the opportunity to offer evidence of the specific prejudice or added costs the sanctionable conduct has caused.

I. BACKGROUND

This multidistrict litigation was transferred to the Middle District of Florida by the Judicial Panel on Multidistrict Litigation on July 10, 2006. Doc. No. 1. On August 15, 2006, Judge Conway entered an order setting the first pretrial status and discovery conference for September 7, 2006. Doc. No. 4. At that hearing there was a substantial discussion as to expectations for the progress of discovery. It was the Court’s expectation that the indisputably relevant material would be produced quickly and without difficulty, despite its volume. Counsel for AZ requested 60 days to complete electronic formatting of the NDA and IND. This extra time was deemed necessary to eliminate the possibility of being unable to meet the Court’s deadlines. Doc. No. 32 at 21. The Court’s reliance on experienced counsels’ ability to accomplish routine matters routinely and timely was in vain.

During the status conference held on November 20, 2006, the Court requested that the parties meet and confer “to submit either agreed proposals to cover document preservation, production protocol and resolution of this issue about formatting of things already produced by December 5, 2006.” Doc. No. 84 at 43. However, instead of submitting an agreed proposal for production protocol and formatting, the parties submitted competing proposals (Doe. No. 99 & 100), apparently without a good faith conference within the meaning of Local Rule 3.01(g). Three days before the December 8, 2006 status conference, the parties finally began discussions about electronic documents being produced with searchable load files, bates-stamped TIFF’s1 and various metadata fields. Doc. No. 100 at 1-2 (December 10, 2006). Following the status conferences before the Court on December 11 — which the Court had to adjourn and carry over to December 12, 2006 because the parties had been unable to agree ahead of time — the parties proposed a Joint Motion to adopt two case management orders. Doe. No. 110.

The Joint Motion stated, “It is the stated policy of AZ counsel, and its client, that commensurate with the goals of these MDL eases to get to Plaintiffs’ counsel in a timely manner and in a format usable the necessary production documents that the opposing side will need to help them develop, evaluate, and understand their cases for purposes of ultimate prosecution and/or dismissal of cases.... It is submitted that [proposed] CMO 2 reflects the confluence of the competing interests of both parties, and reflects a workable, practical and judicially efficient methodology and system for the production of documents to the MDL Plaintiffs.” Doc. No. 110 at 4 (emphasis added). On its face, the proposal did that. Unfortunately, AZ has not lived up to producing discovery in a timely manner or useable format. [653]*653The proposed CMO 2 submitted by the parties set forth deadlines for AstraZeneca’s production of organizational charts for its corporate structure, the Seroquel team, and the drug safety team for the past ten years; listings of 80 (eighty) custodians from whom it is collecting documents; listing of databases concerning document production and preservation; timing for interviews of knowledgeable AstraZeneca IT persons, and the parties’ agreed format of the production of custodial files. Doc. No. 110-3. As the Court commented at the time, “The failure of the Defendant to investigate and understand its own records and documents and to prepare them for production has not met the expectations of the Court as discussed at the September 2006 Conference.” Doc. No. 113. The Court also commented on its misgivings as to the “proposed CMO 2 regarding production and preservation of Defendant’s documents, [which] still seems unduly cumbersome. Nonetheless, if the parties are confident that their agreement will allow them to present issues to the Court for appropriate consideration and disposition without delays engendered by claims of non production of information, the proposal can be approved.” Doc. No. 113.

On January 26, 2007, Judge Conway entered CMO 2 (Doc. No. 129) portions of which were adopted verbatim from the parties’ proposed CMO 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
244 F.R.D. 650, 2007 U.S. Dist. LEXIS 61287, 2007 WL 2412946, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-seroquel-products-liability-litigation-flmd-2007.